A pharmacokinetic interaction between carbamazepine and olanzapine: Observations on possible mechanism

European Journal of Clinical Pharmacology

Volumn 54, Issue 8, 1998, Pages 639-643

  Lucas, R A ^a   Gilfillan, D J ^a   Bergstrom, R F ^b  

^a ELI LILLY AND COMPANY   (United States)

^b WISHARD MEMORIAL HOSPITAL   (United States)

Author keywords

Carbamazeplne; Drug interaction; Olanzapine

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CYTOCHROME; HYDROCORTISONE; OLANZAPINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; ENZYME INDUCTION; FIRST PASS EFFECT; HUMAN; HUMAN EXPERIMENT; MALE; MANIC DEPRESSIVE PSYCHOSIS; NEGATIVE SYNDROME; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIOLOGICAL MARKERS; CARBAMAZEPINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PIRENZEPINE;

EID: 0031770968     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050527     Document Type: Article

References (18)

1. Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S and the Olanzapine HGAP Study Group (1996) Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 124: 159-167
2. Kassahun K, Mattiuz EL, Nyhart E, Obermeyer B, Gillespie T, Murphy A, Goodwin RM, Tupper D, Callaghan JT, Lemberger L (1997) Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 25: 81-93
3. Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ, Swanson SP, Hamman MA, Wrighton SA (1996) Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 276: 658-666
4. Ged C, Rouillon JM, Pichard L, Combarlert J, Bressot N, Bories P, Michel H, Beaune P, Maurel P (1989) The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 28: 373-387
5. Catlow JT, Barton RD, Clemens M, Gillespie TA, Goodwin M, Swanson SP (1995) Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl 668: 85-90
6. Elyas AA, Ratnaraj N, Goldberg VD, Lascelles PT (1982) Routine monitoring of carbamazepine and carbamazepine 10, 11-epoxide in plasma by high-performance liquid chromatography using 10-methoxycarbamazepine as internal standard. J Chromatogr 231: 93-101
7. Gibaldi (1984)
8. Moreland TA, Park BK, Rylance GW (1982) Microsomal enzyme induction in children: the influence of carbamazepine treatment on antipyrine kinetics, 6-beta-hydroxycortisol excretion and plasma gamma-glutamyltranspeptidase activity. Br J Clin Pharmacol 14: 861-865
9. Patsalos PN, Duncan JS, Shorvon SD (1988) Effect of the removal of individual antiepileptic drugs on antipyrine kinetics in patients taking polytherapy. Br J Clin Pharmacol 26: 253-259
10. Anonymous (1996) Physicians desk reference Medical Economics Company, Montvale, New Jersey, pp 853
11. Parker AC, Pritchard P, Preston T, Choonara I (1998) Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. Br J Clin Pharmacol 45: 176-178
12. Jerling M, Lindström L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16: 368-374
13. Brøsen L, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45: 1211-1214
14. Sesardic D, Boobis AR, Edwards RJ, Davies DS (1988) A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-de-ethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 26: 363-372
15. Mäenpää J, Wrighton S, Bergstrom R, Cerimele B, Tatum D, Hatcher B, Callaghan JT (1997) Pharmacokinetic and pharmacodynamic interactions between fluvoxamino and olanzapine. Clin Pharmacol Ther (abstract, in press)
16. Wrighton SA, Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22: 1-21
17. Relling MV, Lin JS, Ayers GD, Evans WE (1992) Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 52: 643-658
18. King DJ, Burke M, Lucas RA (1995) Antipsychotic drug-induced dysphoria. Br J Psychol 167: 480-482